|LETTERS TO THE EDITOR
|Year : 2018 | Volume
| Issue : 1 | Page : 59-61
Relationship between disease activity and Helicobacter pylori infection in patients with vitiligo
Ola Ahmed Bakry1, Mohamed Basha1, Sally El Hefnawy2, Shaimaa Mekkawy1
1 Department of Dermatolog, Andrology and STDs, Faculty of Medicine, Menoufiya University, Egypt
2 Department of Medical Biochemistry, Andrology and STDs, Faculty of Medicine, Menoufiya University, Egypt
|Date of Web Publication||22-Jan-2018|
Ola Ahmed Bakry
Department of Dermatology, Andrology and STDs, Menoufiya Faculty of Medicine, Shebeen El Kom - 32817
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bakry OA, Basha M, El Hefnawy S, Mekkawy S. Relationship between disease activity and Helicobacter pylori infection in patients with vitiligo. Indian Dermatol Online J 2018;9:59-61
|How to cite this URL:|
Bakry OA, Basha M, El Hefnawy S, Mekkawy S. Relationship between disease activity and Helicobacter pylori infection in patients with vitiligo. Indian Dermatol Online J [serial online] 2018 [cited 2021 Aug 5];9:59-61. Available from: https://www.idoj.in/text.asp?2018/9/1/59/223729
Vitiligo is a common dermatologic disease with a debated etiology. Infectious agents have been claimed to trigger disease development through antibody production, molecular mimicry, cytokine production, major histocompatibility complex activation, regulatory T-cell dysfunction, immune complex formation, and chronic inflammatory damage.
Helicobacter pylori (H. pylori) is one of the most common pathogens affecting humans, infecting approximately 50% of the world's population. The prevalence of infection varies in different governorates in Egypt. Reported prevalence in Delta is approximately 70%. Several immune-mediated skin disorders have been considered to have a relationship with H. pylori infection.
The aim of the present study was to evaluate if there is a relationship between active vitiligo and H. pylori infection.
Seventy-five patients with non segmental vitiligo were selected [51 (68%) cases with active disease and 24 (32%) with stable disease]. Seventy-five healthy, age and gender- matched subjects were enrolled as a control group. A written consent form approved by local Ethical Research Committee was obtained from every participant prior to study initiation.
The diagnosis of vitiligo was made on the basis of typical clinical features and Wood's light examination. All studied cases were either newly diagnosed or old patients with completely depigmented lesions. Assessment of disease activity was done according to the Vitiligo Disease Activity (VIDA) score. Clinical data of selected cases and controls are summarized in [Table 1].
Patients with dermatological diseases other than vitiligo, with autoimmune diseases or malignancy, those who took previous H. Pylori eradication treatment, and those using NSAIDs, antibiotics, or proton pump inhibitors in the last month before the study were excluded.
Diagnosis of infection was done by stool antigen test (SAT) which is a noninvasive method with good sensitivity and specificity, in global meta-analysis, in the diagnosis of H. Pylori infection. Measurement of serum IgG antibody was done to avoid the influence of different factors on SAT positivity.
H. pylori specific IgG antibody in serum and SAT were detected by enzyme-linked immunosorbent assay (ELISA). As the presence of antibody may denote active or past infection, included cases with both positive SAT and IgG were designated as having active infection.
For SAT, level <20 ng/ml denotes negative result and level >20 ng/ml denotes positive result.
For H. pylori IgG in serum, level <20 u/ml denotes negative result and level >20 u/ml denotes positive result.
Data were collected, tabulated, and statistically analyzed using a personal computer with SPSS version 11 software (SPSS Inc, Chicago, Illinois, USA). Fisher's exact test was used for comparison of qualitative variables in 2 × 2 tables when expected cell count of more than 25% of cases was less than 5. Chi-square test (χ2) was used to study the association between two qualitative normally distributed variables. Mann–Whitney U test was used for comparison between two groups not normally distributed having quantitative variables. Differences were considered statistically significant with P < 0.05.
H. pylori infection was positive in 49 (65.3%) vitiligo cases compared with 18 (24%) in the control group (P = 0.001)[Figure 1]. In cases, infection was significantly associated with high VIDA score (P = 0.009) and with active disease (P = 0.02) [Table 2].
|Figure 1: Prevalence of H.pylori infection in studied cases and controls|
Click here to view
H. pylori may alter cellular immunity resulting in loss of self-tolerance and autoimmune destruction of melanocytes. This autoimmune reaction results from higher levels of C-reactive protein, chronic inflammatory condition, autoantibody production, and antigenic stimulation. In addition, local inflammation of gastric mucosa leads to release of inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, and IL-1β] that produce systemic inflammation which subsequently affect skin microenvironment with loss of functional melanocytes.
The current study demonstrated significant association between active vitiligo and H. pylori infection. On the contrary, Dogan et al. reported absence of association between H. pylori positivity and vitiligo activity score.Çakmak et al. showed no significant relationship between H. Pylori SAT positivity and activity of vitiligo.
In the current work, positive cases for H. Pylori infection received eradication therapy consisting of omeprazole 20 mg BID, clarithromycin 500 mg BID, and metronidazole 500 mg BID for 14 days.
Follow-up 3 months later showed suppression of disease activity in (11/49) cases.
Non responding cases regarding disease activity may be explained by the multifactorial etiology of vitiligo.
Therefore, it may be useful to search for H. Pylori infection in patients with vitiligo, especially in those with active disease. Clinical trials to evaluate the effect of H. Pylori eradication in infected vitiligo patients are also needed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kivity S, Arango MT, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya JM, et al
. Infection and autoimmunity in Sjogren's syndrome: A clinical study and comprehensive review. J Autoimmun 2014;14:53-5.
Windle H, Kelleher D. Identification and characterization of meyalloprotease activity from H. Pylori, which is capable of degrading immmunoglobulins (abstract). In: 8th
international workshop on gastrodoudenal pathology and H. Pylori. Edenbrugh Scotland 1995; 340:43-49.
Sabah AA, Gneidy MR, Saleh NM. Prevalence of Helicobacter pylori
infection among adult patients with different gastrointestinal parasites in Tanta City. J Egypt Soc Parasitol 2015;45:101-6.
Shankar DS, Shashikala K, Madala R. Clinical patterns of vitiligo and its associated co morbidities: A prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012;3:114-8.
Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis. Am J Gastroenterol 2006;101:1921-30.
Chey W, Wong B. American College of Gastroenterologoy guideline on the management of Helicobacter pylori
infection. Am J Gastroenterol 2007;102:1808-25.
Cutler AF. Testing for Helicobacter pylori
in clinical practice. Am J Med 1996;100:35-41.
Blaser MJ. Helicobacter pylori
and associated diseases. BMJ 1998;316:1507-10.
Gasbarrini A, Franceschi F, Gasbarrini G, Pola P. Extraintestinal pathology associated with Helicobacter infection. Eur J Gastroenterol Hepatol 1997;9:231-3.
Moss S, Calm J. H. pylori and peptic ulcer: The present position. Gut 1994;33:289.
Doǧan Z, Özdemir P, Ekşioǧlu M, Filik L. Relationship between Helicobacter pylori
infection and vitiligo: A prospective study. Am J Clin Dermatol 2014;15:457-62.
Çakmak SK, Tantoglu BH, Onan D. The frequency of Helicobacter pylori
infection in vitiligo patients. Pigment Int 2015; 2:81-4.
Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al
. Current European concepts in the management of Helicobacter pylori
infection - The Maastricht Consensus Report. The European Helicobacter Pylori
Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9:1-2.
[Table 1], [Table 2]